CAPE II

(redirected from Circadian Anti-ischaemia Program in Europe II)

CAPE II

Circadian Anti-ischaemia Program in Europe II. A trial comparing anti-ischaemic calcium-channel blockers—e.g., amlodipine and/or other agents—in managing circadian patterns of transient myocardial ischaemia; CAPE II also compared amlodipine + atenolol or diltiazem + isosorbide for optimal ischaemia suppression.
 
Conclusion
Amlodipine and diltiazem are acceptable as monotherapies to reduce symptomatic and exercise-induced ischemia, but combination therapies are better. In CAPE II, amlodipine/atenolol reduced nitroglycerin consumption and ischaemic episodes.